ACN Newswire

Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031.There remains a critical need for therapies that offer sustained and comprehensive disease control.As a next-generation selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC.The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12). The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY(R) or placebo. The study results showed that, VELSIPITY(R) demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY(R) was consistent with previous studies, with no new safety signals observed. The study confirms the efficacy and safety of VELSIPITY(R) in this population, with results published in The Lancet Gastroenterology & Hepatology.From a clinical value perspective，VELSIPITY(R) is a once-daily oral therapy with rapid onset of action, strong mucosal healing efficacy, and a favorable safety profile. Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University noted that UC is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system. Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse risk, and supports long-term disease management.“UC treatment in China has long faced limited efficacy, high relapse rates, safety concerns, and inconvenient dosing. Despite available biologics and small-molecule therapies, unmet clinical needs persist,” said Prof. Wu Kaichun of the First Affiliated Hospital of AFMU, principal investigator of VELSIPITY(R)’s Asian clinical trial. “Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management.”“Autoimmune diseases have long-term impacts on patients worldwide, with significant unmet clinical needs persisting both in China and globally,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “The approval of VELSIPITY(R) underscores the clinical value of innovative therapies for UC and reflects Everest Medicines’ sustained commitment to advancing drug development in line with international R&D standards. We look forward to expanding our global reach and providing patients with broader access to innovative treatment options.”“Its approval in China addresses a critical unmet medical need and introduces a novel oral therapy promoting deep mucosal healing,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “We are committed to rapidly commercializing VELSIPITY(R) and working toward its inclusion in the National Reimbursement Drug List to further expand patient access and affordability, benefiting more patients across China.”The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis , VELSIPITY(R) was also included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, with strong recommendations supporting its use for both induction and maintenance of remission in patients with moderately to severely active UC. In 2024, VELSIPITY(R) was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. The localized production project for VELSIPITY(R) was launched at the Jiashan manufacturing site in March 2025, supporting its future commercialization in China.The successful approval of VELSIPITY(R) further strengthens Everest Medicines’ product portfolio in the field of autoimmune diseases and also forms a critical part of the 2030 strategy of the Company. This strategy is built on a dual-engine model of business development partnerships and in-house R&D, aiming to generate predictable value through commercialization while building long-term growth momentum through sustained innovation, thereby supporting pipeline continuity and sustainable development.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle.The Company targets annual revenue exceeding RMB10 billion by 2028, and RMB15 billion by 2030 (including approximately RMB9 billion from the existing pipeline and approximately RMB6 billion from newly in-licensed assets). Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafte.Over the same period, the number of commercial products is expected to exceed 20, including NEFECON(R), VELSIPITY(R), XERAVA(R), Lerodalcibep and MT1013.Industry observers widely expect VELSIPITY(R) to become Everest's next blockbuster product, with analysts projecting peak sales of up to RMB 5 billion. As VELSIPITY(R) realizes its commercial potential, Everest's revenue mix and growth trajectory are expected to strengthen further. Looking ahead, Everest Medicines will continue to focus on therapeutic areas with significant unmet clinical needs. Leveraging its established commercialization capabilities and in-house R&D, the company aims to accelerate the launch of innovative therapies with global competitiveness, drive sustainable growth, and create greater health value for patients and society.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

云顶新耀维适平(R)获中国国家药品监督管理局批准上市 为中重度溃疡性结肠炎治疗提供新选择

香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀今日宣布，中国国家药品监督管理局（NMPA）已批准维适平(R)（精氨酸艾曲莫德片, VELSIPITY(R)）的新药上市许可申请（NDA），用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性溃疡性结肠炎成人患者。溃疡性结肠炎是一种病因尚不明确、易复发的慢性肠道炎症性疾病。近年来，中国溃疡性结肠炎发病率持续上升，并呈现年轻化趋势，预计患者人数将由2025年的约98万增长至2031年的约150万。疾病对患者生活质量带来长期负担，临床亟需实现更加稳定、持久的疾病控制。作为新一代高选择性S1P受体调节剂，维适平(R)每日一次口服，可实现快速起效和强效深度黏膜愈合，并具有良好的安全性特征，具备最佳药物（best-in-disease）潜质，为成人溃疡性结肠炎患者提供新的一线治疗选择。据悉，维适平(R)此次获批，是基于亚洲多中心III期注册临床ENLIGHT UC研究（ES101002）的结果和全球III期注册研究ELEVATE UC（包括ELEVATE UC 52和ELEVATE UC 12研究）的结果。ENLIGHT UC研究是迄今完成的最大规模亚洲中重度活动性溃疡性结肠炎患者的III期注册临床研究，总计纳入340名患者。结果显示，维适平(R)治疗组在所有主要和次要疗效终点上均达到统计学显著性与临床意义，且安全性良好。研究结果已发表于国际顶级学术期刊柳叶刀子刊《The Lancet Gastroenterology & Hepatology》。从临床价值来看，维适平(R)凭借每日一次口服的治疗方案，能够快速起效并达到临床缓解，同时还在黏膜愈合和组织学改善等方面疗效显著，同时安全性良好。对此，中华医学会消化病学分会前任主任委员、炎症性肠病学组组长、中山大学附属第一医院消化内科学术带头人、首席专家陈旻湖教授指出，我国目前正处于溃疡性结肠炎发病率和患病率快速上升阶段，该疾病常反复发作，严重影响患者生活质量，对个人、家庭和医疗资源造成沉重负担。实现黏膜愈合有助于更有效地控制症状，降低复发风险，改善患者生活质量。黏膜愈合是国内外临床指南公认的溃疡性结肠炎治疗目标，这不仅关系到疾病的长期症状缓解，也与改善患者生活质量密切相关。维适平(R)亚太临床试验牵头研究者、世界胃肠病组织执委兼司库、亚太地区消化病学会副主席、中华医学会消化病学分会第十、十一届副主委、空军军医大学西京消化病医院吴开春教授指出，长期以来，我国溃疡性结肠炎治疗面临传统疗法疗效有限、给药便捷性差以及不良反应多等诸多局限。已获批的生物制剂和小分子治疗也存在"疗效天花板"及"失应答"等问题。维适平(R)通过调控淋巴细胞迁移，从源头控制肠道炎症，并促进黏膜愈合。在多个临床研究中维适平(R)展现出显著疗效，尤其在快速起效、实现无激素缓解及深度黏膜愈合方面具有明显临床优势。此次获批标志着维适平(R)从临床研究到上市的完整验证，为患者提供创新治疗选择，并推动中重度溃疡性结肠炎管理进入新阶段。云顶新耀董事会主席吴以芳表示："自身免疫性疾病在全球范围内对患者造成长期而深远的影响，在中国乃至全球范围内，仍存在大量尚未满足的临床需求。维适平(R)的获批不仅体现了创新疗法在溃疡性结肠炎治疗中的临床价值，也彰显了公司坚持以国际研发标准推进创新药物发展的长期战略。我们期待通过持续拓展全球化布局，让更多患者受益于高质量、具有突破性的治疗选择。"云顶新耀首席执行官罗永庆表示: "此次维适平(R)在中国的获批，填补了中重度溃疡性结肠炎治疗领域的重要空白，并为以深度黏膜愈合为目标的创新口服治疗提供了新的选择。公司将加快推进维适平(R)的商业化进程，并积极推动纳入国家医保目录，持续提升创新疗法在中国的可及性和可负担性，让更多患者受益。"值得一提的是，维适平(R)的临床价值已获得多项国际权威指南的充分认可，被先后纳入2024年美国胃肠病协会（AGA）临床实践指南及2025年美国胃肠病学院（ACG）临床指南，并获强烈推荐。此前，该药已于2024年和2025年被列入粤港澳大湾区内地9市临床急需进口港澳药品医疗器械目录（文件中名称为"伊曲莫德"）。目前，维适平(R)已在美国、欧盟以及中国大陆、中国香港、中国澳门、新加坡等多个国家和地区获得新药上市批准。2025年3月，云顶新耀启动维适平(R)嘉善工厂建设项目，为本地化生产及长期可及性提供有力支持。维适平(R)的成功获批，进一步夯实了云顶新耀在自身免疫疾病领域的产品布局，也是公司2030年发展战略的重要组成部分。该战略以"BD合作 + 自主研发"双轮驱动为核心，致力于通过商业化实现确定性价值，同时通过持续创新研发构建长期成长动能，推动管线的延续性与可持续发展。在商业化平台建设上，云顶新耀已布局三款商业化产品，并着力建立全渠道商业化体系及药品全生命周期商业化能力。计划到2028年实现收入规模超过100亿元人民币，而到2030年收入规模超过150亿元人民币（其中现有管线销售收入约90亿元人民币而新引进管线销售收入约60亿元人民币）；收入的年复合增长率预计在2025至2030年超过50%，2030年后保持超过15%。同时，商业化产品数量将提升至20款以上，包括耐赋康(R)、维适平(R)、依嘉(R)、乐瑞泊(R)（莱达西贝普）及MT1013等。业内普遍认为，维适平(R)有望成长为云顶新耀又一重磅产品，其销售峰值预计可达50亿元人民币。随着维适平(R)商业化进程的持续推进，公司整体收入结构与成长曲线有望进一步优化。未来，云顶新耀将继续聚焦重大未满足临床需求，持续强化差异化创新管线，加速推进具有国际竞争力的创新疗法落地，助力公司实现可持续成长，并为患者与社会创造更大的健康价值。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025

The accolades underscore Malaysia’s leading mineral water brand’s international achievements in their consistent pursuit of quality, excellence and industry leadershipKUALA LUMPUR, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) - Spritzer Berhad (“Spritzer” or “the Company”), Malaysia’s leading natural mineral water brand started the year on a strong note with a repeat of the annual recognition by two prestigious platforms, the Putra Brand Awards 2025 and the Superior Taste Award 2025. These achievements, their 10th and 15th recognition for each award respectively, reinforce Spritzer’s continued efforts and commitment to excellence, innovation and uncompromising standards in delivering high-quality natural mineral water locally and internationally.Spritzer Wins the Gold at the Putra Brand Awards 2025Spritzer was awarded the Gold Award in the Beverage – Non-Alcoholic category at the Putra Brand Awards (PBA) 2025, marking its 10th impressive win in the category, further reaffirming its status as Malaysia’s most trusted natural mineral water brand. The Putra Brand Awards are uniquely consumer-driven, with winners selected solely by Malaysian consumers as the judge of brand excellence across 30 categories. As a genuine reflection of the brand’s enduring consumer affinity, market confidence and brand relevance, the accolade is particularly meaningful.Spritzer’s win as the only mineral water brand amidst other well-loved global beverage brands in Malaysia highlights Spritzer’s competitiveness and firm standing in the national beverage landscape. The award was proudly accepted by Dr. Chuah Chaw Teo, Research and Development (R&D) Director of Spritzer, on behalf of the Company.“Winning the Putra Brand Awards for the 10th year affirms our consistent efforts to keep improving over the years,” said Dr. Chuah. “Behind this recognition lies years of disciplined research and development (R&D), stringent quality control, and continuous improvement across our operations and customer touch points. Our priority has always been to safeguard the integrity of our natural mineral water while innovating responsibly to meet the evolving needs of consumers and businesses.”Photo 1 and 2: Spritzer celebrates its Gold Award in the Beverage - Non-alcoholic Category at The Putra Brand Awards 2025A Superior Triumph in Taste GloballySpritzer’s product excellence was further validated internationally at the Superior Taste Award 2025, a globally respected certification conferred by the International Taste Institute in Brussels, Belgium known for its rigorous, professional sensory evaluation of food and beverage products. In 2025, Spritzer Natural Mineral Water secured the prestigious 3-Star Superior Taste Award for the 10th year, a milestone that continues to build on Spritzer’s 15-year legacy of recognition by the International Taste Institute.This long-term acclaim reflects the brand’s unwavering dedicated to delivering natural mineral water of exceptional quality and taste. It reaffirms Spritzer’s strong product capabilities, from taste profile to mineral composition, and its commitment to upholding stringent international benchmarks, further cementing its dominance in Malaysia’s bottled water sector and boosting consumer assurance across local and global markets.Established in 2005, the International Taste Institute is known for its independent, blind tasting methodology, conducted by a panel of over 250 world-class chefs and sommeliers from more than 20 countries worldwide. Products are assessed against strict sensory criteria and only those achieving a score above 70% are certified with the Superior Taste Award, with distinctions awarded based on performance.Photo 2: Spritzer secured the prestigious 3-Star Superior Taste Award for the 10th year for Spritzer Natural Mineral WaterReinforcing Trust Across Markets and StakeholdersTogether, these two awards signify strong domestic consumer confidence and international endorsement of product quality. Backed by robust R&D processes, consistent quality management and a long-standing heritage rooted in nature, Spritzer continues to demonstrate reliability and leadership in the industry.Dr. Chuah concluded, “These speak to the trust that consumers place in us every day. Spritzer remains committed to protecting the purity of our source, strengthening our innovation pipeline, and continuing to deliver natural mineral water of the highest quality that Malaysians and global consumers can rely on.”Supported by its partners, customers, and dedicated team, the Company will continue to represent Malaysian quality on the global stage.For more high-resolution photos, please download them here.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottle.For more information, visit www.spritzer.com.myFor media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

「工业数智化引擎」卡奥斯冲击港交所 激活制造业新动能

香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 在全球制造业进入「再工业化」与「数字化重构」并行的新阶段，工业数智化已不再是可选项，而是企业提升长期竞争力的必选项。 卡奥斯物联科技股份有限公司（「卡奥斯」），正是这场产业变革的引领者。根植于海尔集团40余年智能制造积淀与大规模定制模式创新实践，卡奥斯以工业大模型驱动的COSMOPlat平台为核心，早已突破传统解决方案供应商的边界，进化为开放、协同、不断自我进化的工业数字生态的构建者。 1月30日，卡奥斯正式向港交所递交上市申请，旨在通过港股上市，将其工业数智化能力，带向更广阔的全球市场。技术赋能产业：COSMOPlat 引领工业转型升级从行业层面看，工业数智化正处于由「系统建设期」向「平台扩展期」过渡的关键阶段。根据Frost &Sullivan数据，2024年，中国工业数智化解决方案市场规模达到2.0万亿元。 相比一次性交付的项目模式或单一解决方案销售，基于工业大模型与智能体技术的工业互联网平台，能够通过能力沉淀和模型复用，实现跨系统的数据接入与统一治理，获得更高的边际效率与更强的客户黏性，其优势将持续凸显。卡奥斯的核心竞争力，正在于其自主开发的COSMOPlat工业互联网平台，其构建了工业智能软件与智能体应用、工业作系统与工业大脑、物联系统与边缘计算深度融合的一体化技术架构，以端云一体的数据智能与物联网产品及解决方案，全方位赋能企业数智化转型。COSMOPlat平台以工业大模型核心驱动力，该模型为国内首个基于工业互联网平台的工业大模型，依托海尔集团40余年制造业经验、天数工业大数据平台积累的专家模型与高质量多模态数据集研发而成，可支持研发设计、生产制造、运营服务、 双碳管理等主要工业场景的数智化。 基于天智工业大模型，卡奥斯将智能体应用与工业场景充分融合，打造了覆盖3大行业、40余个核心场景的工业智能体，帮助客户缩短研发周期、提高生产效率、降低用能成本。卡奧斯依託工業互聯網平台，將製造業全流程解構為需求交互、研發、營銷、採購、生產、物流、服務七大模塊，把復雜流程封装為可複製、可推廣的工業智能軟件與端雲一體化解決方案，有力支撐跨行業、跨領域推廣應用，实现从「服务单个企业」到「激活整个产业集群」的价值跃升。目前，卡奥斯已与家电、能源化工等行业的一批龙头企业、专精特新企业和园区客户建立战略合作，共同探索基于工业互联网平台的数智化转型新路径，为客户打造17座灯塔工厂，全球数量最多、覆盖行业最广。不仅如此，标杆项目的示范效应还能带动公司快速切入新行业、获得新客户，形成老客户复购与新客户引流的扩散效应，从单一产品的复购延伸至全链条服务，实现从「单点赋能」到「全场景绑定」，增厚公司业绩弹性。 截至2025年9月，卡奥斯已累计链接企业超16万家，其中付费企业达9500余家，生态规模与商业价值同步提升。全球布局：中国方案的世界表达卡奥斯的另一大看点，是其作为中国工业智能化「方案输出者」的全球定位。 作为中国工业互联网平台出海的先行者，卡奥斯正将成熟的数智化模式推向全球，成为中国智造「走出去」的核心载体。截至2025年9月30日，卡奥斯的解决方案已在全球16个国家推广，在美国、新西兰、意大利等国家的70余座工厂成功落地。 在东南亚，其布局的智能控制器研发制造中心正快速渗透当地电子制造产业链; 在北美，凭借服务海尔集团海外家电互联工厂的经验，公司成功切入当地智能家居领域。 卡奥斯全球化布局的独特之处在于，它不是简单的市场扩张，而是一种更高维度的「软实力」出海，即将其在国内经过验证的工业数智化模式进行全球输出。 2025年前3季度，公司海外收入占比超12%，形成稳定的海外增长曲线。更为深远的影响体现在国际标准制定领域。 卡奥斯是首家被IEEE、ISO、IEC和UL四大国际标准组织共同批准主导制定工业互联网和大规模定制国际标准的平台，也是首个被欧洲联邦云（GAIA-X）邀请参与共建平台的非欧盟企业，累计主导、参与制定国际标准12项，国家行业标准98项。 通过将技术优势转化为国际规则，卡奥斯为中国在全球工业数字化领域赢得了重要话语权，为后续全球化扩张铺平道路。卡奥斯赴港上市，恰逢全球制造业加速智能化转型、中国数字经济与实体经济深度融合的关键时期。 凭借以AI技术赋能的工业互联网平台，卡奥斯已积累庞大用户基础，更以中国方案输出模式推进全球化布局，持续拓宽增长边界。 平台能力、生态结构与全球复制经验的叠加，让卡奥斯早已超越单一工业互联网服务商的定位，进化为未来工业生态的构建者和中国智造出海的标杆。随着生态成员的持续扩容、国际标准话语权的深化以及新兴市场的加速渗透，卡奥斯的成长潜力将持续释放。 对于关注中国科技出海与全球制造业复苏的国际资本而言，卡奥斯不仅是分享工业数智化红利的优质标的，更有望凭借中国工业技术与生态模式，在全球工业变革浪潮中书写生态共荣、价值共创的全新篇章。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

Eternal Beauty Holdings Limited and Lane Crawford Debut Landmark Fragrance, Further Expanding Footprint in High-Margin Niche Fragrance Market

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Eternal Beauty Holdings Limited (“Eternal Beauty” or the “Group”) (Stock Code: 6883.HK), a pioneer in China’s beauty and fragrance industry, announced its first-ever collaboration with Lane Crawford, a premier luxury department store, to launch an exclusive boutique niche fragrance section at its Harbour City store in Tsim Sha Tsui. The collaboration aims to further advances the Group’s strategy focused on high-margin niche fragrance brands, strengthens its premium brand footprint through an elite retail network, and captures the growing profit opportunities in the niche fragrance for Chinese Mainland and Hong Kong markets.The zone brings together four international niche fragrance brands under the immersive concept of a "Luxury Niche Perfume Street" with European flair, featuring Atkinsons, Clive Christian, Memo Paris and SOLFÉRINO, each presented with its unique style and heritage. Clive Christian and SOLFÉRINO are making their debut in Hong Kong, offering a rare experience to local high-end consumers. By leveraging Lane Crawford’s premium retail network that reaches high-spending customers, the Group effectively enhances brand penetration in the Hong Kong market. This initiative successfully introduces the Group’s portfolio into a core upscale retail destination in Hong Kong, demonstrating the Group’s strengths in channel expansion and retail curation, while further solidifying its brand influence and long-term growth momentum in the niche fragrance portfolio.Brand Introduction:AtkinsonsThe 200-year-old British "Royal Fragrance House" reinvents the rebellion and elegance of 19th-century English gentlemen, transforming historical formulas into a modern, contemporary aura.Clive ChristianThe first exclusive collectors’ boutique in Hong Kong: Clive Christian is a luxury British perfume house that creates the world's finest perfumes. A legacy of British craftsmanship, unparalleled quality in concentration and complexity, unashamedly indulgent and luxurious presentation.Memo ParisMemo Paris is a Parisian fragrance house, see each fragrance as a travel note captured in scent. Preserve memory of a journey to unique destination. Memo Paris sketches a delicate, emotional map of the world: a universe where memories become scents.SOLFÉRINODebuting brilliantly in Hong Kong, SOLFÉRINO is born in Paris, France, the brand draws inspiration from the historic architecture of this City of Lights, showcases French elegance with exceptional craftsmanship and presenting Parisian audacity and creativity.Ms. Wendy Lau, Executive Director of Eternal Beauty and Chairman of the International Fragrance Association, said, “With over 40 years of industry experience, Eternal Beauty has cultivated sharp market vision, distinctive taste, and profound expertise. This enables the Group to accurately identify and introduce brands that align with market trends and carry strong profit potential into the Greater China market, which continues to demonstrate vigorous consumption upgrade momentum. We are thrilled to partner with Lane Crawford, an influential luxury department platform in Asia, to create this exclusive boutique niche fragrance section in Hong Kong’s core luxury shopping district, leveraging the Group’s strengths in niche fragrance brand management and retail channel development. This is not only an important step for the Group to deepen the niche fragrance market, but also a concrete manifestation of our niche fragrance brand expansion strategy. Moving forward, the Group will continue to explore collaborations with top-tier retail partners. By introducing more niche brands with high growth potential, it will strengthen its long-term growth momentum and enhance sustainable profitability in the fragrance market.”Hong Kong's fragrance market continues to benefit from the momentum of the emotional economy, demonstrating relatively resilient growth against the backdrop of a steady recovery in the overall retail sector. In December 2025, the value of total retail sales in Hong Kong increased by 6.6% YoY; according to market’s outlook reports, the total retail sales in Hong Kong are expected to grow by nearly 8% in 2026, reaching approximately HKD 410 billion, indicating a continued recovery in local consumer demand. Ms. Chole Lam, Executive Director and Chief Executive Officer of Eternal Beauty, said, “In recent years, experiential retail and emotional consumption have gradually emerged as new retail trends, with emotional value playing an increasingly significant role in consumer decision-making. The ability to establish emotional resonance with consumers is becoming an important direction for brand expansion and product innovation. Emerging consumption segments, represented by high-end and niche fragrances, are more being regarded as categories that carry emotional value and lifestyle propositions, highlighting their growth potential in the retail recovery process.”Eternal Beauty has established an omni sales channel network over 400 cities across Chinese Mainland, Hong Kong and Macau. The cooperation with Lane Crawford is an important part of the Group’s retail channel strategy, aiming to enhance the consumer experience and sales conversion by leveraging the prime location and high customer traffic of the premium department store.Photo CaptionEternal Beauty and Lane Crawford debut landmark niche fragrance zone, bringing together four international niche fragrance brands under the concept of a "Luxury Niche Perfume Street". The zone immersively showcasing four distinctive and heritage-rich brands: Atkinsons, Clive Christian, Memo Paris, and SOLFÉRINO.Please download more high-resolution photos via link:https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharingAbout Eternal Beauty Holdings LimitedEternal Beauty Holdings Limited is the largest perfume group (apart from brand-owner perfume groups) in China (including Hong Kong and Macau) in terms of retail sales in 2023. It primarily sells and distributes products procured from third-party brand licensors, and deploys market for these brand licensors, offering such services as brand management, and designing and implementing customized market entry and expansion plans for their brands. The Group boasts large and diversified brand portfolios that include not only perfumes, but also color cosmetics, skincare products, personal care products, eyewear and home fragrances. As at 30 September 2025, it conducted product distribution and market deployment for a total of 74 external brands, including Hermès, Van Cleef & Arpels, Chopard, Albion and Laura Mercier, with products in different pricing tiers and of versatile features that meet the differentiated demands of consumers in Chinese Mainland, Hong Kong and/or Macau. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

颖通控股与连卡佛携手打造首个顶级小众香水殿堂 进一步拓展高毛利小众香氛市场版图

香港, 2026年2月6日 - (亚太商讯 via SeaPRwire.com) - 中国香水产业领航者颖通控股有限公司（「颖通控股」或「集团」）（股份代号：6883.HK）宣布与顶级奢侈品百货连卡佛达成首度合作，于尖沙咀海运大厦连卡佛内设立首个小众香水限定专区，进一步落实集团聚焦高毛利小众香水品牌的发展策略，并透过顶级零售网络深化高端品牌布局，把握中国内地及香港高端香氛市场持续增长所带来的盈利机遇。​专区云集四大国际高端香氛品牌，以充满欧洲风情的「高级小众香水街」为概念，沉浸式呈现 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四个各具风格与传承的品牌。Clive Christian 及 SOLFÉRINO 更是首度登陆香港，为本地高端消费者带来独家体验，并藉助连卡佛覆盖高消费客群的优质零售网络，有效提升品牌在香港市场的渗透率，进一步将集团旗下品牌引入香港核心高端零售据点，展现集团在渠道拓展与零售策展方面的实力，巩固于高端香氛市场的品牌影响力及长期增长动能。品牌介绍：Atkinsons拥有二百年历史来自英国的「皇室御用香氛品牌」，重塑十九世纪英伦绅士的叛逆与优雅，将历史配方化为现代摩登气息。Clive Christian香港首间典藏级专柜：源自英国伦敦的 Clive Christian 被誉为「世界最奢华的香水之一」，致敬英国皇室贵族经典与顶级奢华工艺传承，彰显无可比拟永恒优雅的底蕴。Memo Paris来自法国的 Memo Paris 以旅行与记忆为灵感，以香气铭记旅途故事，绘制一幅诗情画意的香氛情感地图，将世界景致汇聚于瓶中。SOLFÉRINO首次于香港耀目登场的 SOLFÉRINO 诞生于法国巴黎，灵感源自这座光之城的历史建筑，以精湛工艺诠释法式优雅，创作前卫而富创意的香气。颖通控股执行董事及国际香氛协会主席刘颕贤女士表示：「凭借四十余年的行业经验，颖通积累了敏锐视野、独到品味与深厚专业知识，得以精准甄选契合市场趋势且具备盈利潜力的品牌，并引入蕴藏巨大消费升级动能的大中华市场。我们很高兴与亚洲具影响力的奢侈品百货连卡佛携手，在香港核心奢侈品商圈打造首个小众香水专区，充分发挥颖通在高端香氛品牌运营与零售渠道布局方面的专长。这不仅是集团深化小众香水市场的重要一步，更是我们高端香氛品牌布局策略的具体实践。未来，集团将持续探索与顶级零售伙伴的合作机会，引入更多具高成长潜力的小众品牌，进一步强化集团在高端香氛市场的长期增长动能与可持续盈利能力。」香港香氛市场持续受惠于情绪经济带动，在整体零售业稳步复苏的环境下，展现出相对强韧的增长势头。2025年12月，香港零售业总销货价值按年上升6.6%；而根据市场展望报告预测，2026年香港零售总额有望增长近8%，达到约4,100亿港元，显示本地消费需求正持续回暖。 颖通控股执行董事兼首席执行官林荆女士表示：「近年，体验式零售和情绪消费渐成为零售新潮流，情绪价值在消费决策中的比重明显提升，能否与消费者建立情绪共鸣，正日益成为品牌拓展与产品创新的重要方向。以高端与小众香氛为代表的新兴消费板块，愈来愈多地被视为承载情绪价值与生活方式主张的品类，显示其在零售复苏进程中的增长潜力。」颖通控股已建立覆盖中国内地、香港及澳门逾400个城市的全渠道销售网络，是次与连卡佛的合作为集团零售渠道升级策略的重要一环，旨在透过高端百货的黄金地段与客流量，提升品牌消费体验与销售转化。图片说明颖通控股与连卡佛合作开设首个小众香水专区，云集四大国际高端香氛品牌，以充满欧洲风情的「高级小众香水街」为概念，沉浸式呈现 Atkinsons、Clive Christian, Memo Paris 及 SOLFÉRINO 四个各具风格与传承的品牌。请通过此链接下载更多高清图片：https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharing关于颖通控股有限公司颖通控股有限公司是中国（包括香港及澳门）最大的香水集团（除品牌所有者香水集团外，按2023年零售额计），主要从事销售及分销从第三方品牌授权商采购的产品及为该等品牌授权商进行市场部署，例如为其品牌设计及实施定制的市场进入及扩张计划。颖通控股拥有庞大且多元化的品牌组合，不仅包括香水，还包括彩妆、护肤品、个人护理产品、眼镜及家居香氛。截至2025年9月30日，颖通控股为合共74个外部品牌进行产品分销及市场部署，包括 Hermès、Van Cleef & Arpels、Chopard、Albion及Laura Mercier，涵盖多元化的定价层次及功能，迎合中国内地、香港及或澳门消费者的差异化需求。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

歌礼制药-B（01672）获新加坡政府投资公司入股6412.8万股 涉资约1亿美元

香港, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 根据香港联交所披露的文件，新加坡政府投资公司（GIC Private Limited）入股歌礼制药，以每股均价12.18 港元，买入 64,128,000 股普通股股份，合计涉资约7.81亿港元，折合约1亿美元。入股完成后，GIC持有歌礼制药64,128,000股股份，占公司已发行股本约6.42%，正式跻身公司主要机构股东行列。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, GIC Private Limited made its equity investment in Ascletis Pharma by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

贸发局主办全球最大一站式珠宝商贸平台 荟萃环球珍品 新设硬足金展馆展现黄金崭新技术

香港, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 由香港贸易发展局（香港贸发局）主办的全球最大一站式珠宝商贸平台，将于3月初以「两展两地」的成功模式揭幕。第12届香港国际钻石、宝石及珍珠展于3月2至6日在亚洲国际博览馆举行，展出各类珠宝原材料。第42届香港国际珠宝展则于3月4至8日假湾仔香港会议展览中心举办，展示各款珠宝首饰成品。香港贸发局副总裁古静敏表示：「今届珠宝双展将云集逾40个国家及地区、约4,000家展商，当中七成来自香港以外的地区，其中巴西、阿联酋和印度展商更扩大参展规模，而乌兹别克更是首次参展。香港贸发局积极打造全球最大一站式珠宝商贸平台，凸显香港作为国际商贸及珠宝採购中心的地位。」回顾环球珠宝市场，2025年本港贵重珠宝出口至东盟录得51%升幅，而出口至英国、澳洲及瑞士的增长分别按年上升36%、28%及10%。两展云集逾40个展团 硬足金展馆开启金饰新篇章珠宝双展一直备受环球业界支持，今年云集超过40个展团，当中包括中国内地、台湾、印度、以色列、韩国、缅甸、新加坡、斯里兰卡、泰国、乌兹别克、比利时、德国、意大利、西班牙、土耳其、巴西、哥伦比亚、墨西哥及美国等。世界黄金协会将首设硬足金展馆，合共11家中国内地展商，向国际市场展示崭新黄金技艺，目标以展会作「出海」平台，开拓环球商机。此外，今年香港表厂商会首次组团参展，来自湖北的竹山绿松石展团也首度亮相。而坦桑石协会、彩色宝石协会、亚太区创作师协会及亚洲珠宝文化设计工艺协会亦将继续参展，香港珠宝玉石厂商会将联同Italian Exhibition Group（IEG）再度设馆，展示制造珠宝的最新设备和技术。国际品牌 瞩目登场香港国际珠宝展的「品牌精粹廊」展区（Hall of Fame）载誉归来，规模较去年增加逾四成，匯聚更多国际知名珠宝品牌；其中土耳其领先钻石珠宝品牌 Zen Diamond（展位：CEC 3B-C12）将带来採用精细裁切工艺的钻戒系列。于「珠宝精粹廊」展区（Hall of Extraordinary），香港展商恒和钻石（展位：CEC GH-C07）则展出一枚18K白金及玫瑰金镶嵌蓝钻与浅彩粉钻戒指。 另一香港展商Unique Brilliant Limited（展位：CEC GH-C13）将展示一套项链与耳环组合，红宝石未经加热处理，呈现珍稀的「鸽血红」（pigeon blood red）色泽。东方美学展现非遗工艺今年展会云集多款承载东方文化的珠宝。来自中国内地的广东嘉宝阁传世珠宝（展位：CEC GH-A16），带来以国家级非遗工艺「花丝镶金」，以人手制作的蝴蝶胸针，耗时逾四个月。另一内地展商赛菲尔珠宝（展位：CEC 3E-E02）则带来了「宫廷新中式」风格的作品，运用六项古法黄金工艺制作而成，将传统技艺展现在当代首饰上。内地近年兴起硬足金技术，高纯度和高硬度的特性，令金饰可以融入更多时尚和现代设计元素。由世界黄金协会举办的研讨会将分析最新的黄金市场情况和硬足金技术。展会期间将举行多场关于东方美学珠宝的活动。香港珠宝首饰业商会主办的香港国际时尚足金饰设计比赛，鼓励设计师创作出迎合东盟及中东年轻市场，兼具文化内涵和商业潜力的金饰作品，颁奖典礼将于展会期间举行。由香港玉器商会主办，首届国际翡翠玉器首饰设计大赛2026亦会在展会期间举行颁奖典礼。创意设计领潮流紧贴潮流及具创意的产品有助业界突围而出。有展商将创新构思化成潮流产品，Austy Lee Company Limited（展位：CEC 1E-F32）趁马年将至，推出以斑马纹理为设计灵感的手镯。今年「珠宝设计精选」展区（Designer Galleria）迎来新展商Zheng Hong Collective（展位：CEC 1CON-067A），带来一款飞鱼胸针，佩戴时翅膀和尾端会随身体而摆动。今年香港珠宝设计比赛以「未琢之韵．自然之美」为题，启发本地学生及业界精英以作品演绎大自然之美与设计故事，凸显珠宝设计的多元面貌，大会将于展会期间公佈赛果。稀世瑰宝闪耀双展两展一直为买家网罗古典珍藏及稀有珠宝，香港国际珠宝展的香港展商拾玑古董珠宝（展位：CEC CH-F13）展出20 世纪、70 年代制作的布契拉提粉色蓝宝石套装。另有展商 World Coins Co., Ltd. （展位：CEC CH-N12）带来19世纪意大利工匠的双色珐琅钻石首饰，首饰连同原盒完整保存至今超过100年。香港国际钻石、宝石及珍珠展则有德国展商Caram e.K. （展位：AWE 8-F05）带来18.98卡AGL认证、收藏级的天然粉红蓝宝石；加大拿展商Korite Ammolite Ltd（展位：AWE 8-F35）展示18K金AA级斑彩石配钻石颈鍊。活动方面，香港国际珠宝展将举行「珠宝风格从何而来？探究时代与工艺的印记」座谈会，特别邀请英国着名歷史学家及珠宝权威 Dr. Jack Ogden主讲，深入剖析珠宝工艺演进及时代审美变迁。逾20场论坛活动 探讨AI及网络营销等业界热话珠宝双展期间将举行超过20 场行业讲座与交流活动，涵盖行业趋势、网络营销和珠宝科技等，其中香港国际珠宝展第二日将剖析人工智能如何由设计走到商业化，推动珠宝行业发展。另外大会将安排研讨会，网红分享如何利用电商平台提高珠宝品牌的影响力、增加销售和实践经验等，让业界加快打通线上线下的协同合作渠道。体验与服务并重 全球买家首选平台展览吸引环球大型珠宝零售连锁店、高端、轻奢及设计师珠宝品牌到场採购，为买卖双方缔造商机，并推动业界交流。此外，香港贸发局为持续优化世界各地买家来港採购的体验，联同香港旅游发展局及多家企业推出买家专属优惠，涵盖餐饮、机票、酒店等，让参观珠宝双展的买家，同时感受香港独有魅力。大会将安排免费穿梭巴士，接载买家往返亚洲国际博览馆及市区（包括湾仔香港会议展览中心），详情请参阅展会网站。线上线下相结合 便利入场洽商採购今年珠宝双展将沿用「展览+」（EXHIBITION+）线上线下融合模式，除了在展会现场採购，由2月23日至3月13日，「商对易」(Click2Match）的人工智能会为展商及买家提供线上商贸配对。在场买家则可利用「扫码易」（Scan2Match）扫描展商的二维码，于展会期间或之后随时随地于线上洽谈。在买家入场方面，「香港贸发局商贸平台」流动应用程式（HKTDC Marketplace App）及两展的官方网页都提供网上验证功能。买家只需透过上述平台登记、上传照片和有效证件，即可获取已验证的买家证，无需现场排队登记或验证，大大提升採购效率。图片下载︰https://bit.ly/4ayrcAo香港贸发局副总裁古静敏（中）、香港贸发局珠宝业谘询委员会主席周允成（左）以及香港贸发局香港国际珠宝展及香港贸发局香港国际钻石、宝石及珍珠展筹备委员会主席黄绍基（右），出席今天（2月5日）举行的香港国际珠宝展和香港国际钻石、宝石及珍珠展新闻发佈会。古静敏（前排左三）连同一众香港贸发局香港国际珠宝展及香港国际钻石、宝石及珍珠展筹备委员会委员，以及表演嘉宾合照。艺人陈晓华（右三）率领一众模特儿演绎各款瑰丽珠宝。艺人陈晓华佩戴展商安东公司带来的天然缅甸翡翠套装，碧绿晶莹的翡翠钻石颈链、戒指及耳环，设计高贵优雅。凤凰常见于中式婚嫁饰品，象徵吉祥、如意，展商老凤祥带来富有中式魅力的国潮婚嫁系列，打造女性宫廷般尊贵的饰品。相关网页 香港国际珠宝展展览网页http://hkjewelleryshow.hktdc.com/tc两展穿梭巴士安排https://www.hktdc.com/event/hkjewellery/tc/travel-to-fairground-hkcec展会活动https://www.hktdc.com/event/hkjewellery/tc/intelligence-hub  香港国际钻石、宝石及珍珠展展览网页http://hkdgp.hktdc.com/tc两展穿梭巴士安排https://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-awe展会活动https://www.hktdc.com/event/hkdgp/tc/intelligence-hub香港贸发局新闻中心：http://mediaroom.hktdc.com/tc传媒查询香港贸易发展局传讯及公共事务部：简惠宜电话：(852) 2584 4055电邮：winnie.wy.kan@hktdc.org黄家欣电话：(852) 2584 4524电邮：katy.ky.wong@hktdc.org张敏萱电话：(852) 2584 4137电邮：jane.mh.cheung@hktdc.org香港贸易发展局简介香港贸易发展局(香港贸发局)是于1966年成立的法定机构，负责促进、协助和发展香港贸易。香港贸发局在世界各地设有超过50个办事处，其中13个设于中国内地，致力推广本港作为双向环球投资及商业枢纽。 香港贸发局通过举办国际展览会、会议及商贸考察团，为企业(尤其是中小企)开拓内地和环球市场的机遇。香港贸发局亦通过研究报告和数码资讯平台，提供最新的市场分析和产品资讯。有关香港贸发局的其他资讯，请浏览www.hktdc.com/aboutus/tc。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

HKTDC to host world’s largest one-stop jewellery marketplace

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one-stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld-Expo and will feature a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre and will showcase finished jewellery pieces.Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with 70% coming from outside Hong Kong. Exhibitor participation from Brazil, United Arab Emirates and India has expanded, and Uzbekistan joins for the first time. The HKTDC presents the world’s largest one-stop jewellery marketplace to highlight Hong Kong’s status as an international trade capital and jewellery sourcing hub.”In reviewing the global jewellery market, Hong Kong’s export volume of premium jewellery to ASEAN recorded a 51% increase, while exports to the United Kingdom, Australia and Switzerland grew year-on-year by 36%, 28% and 10% respectively.Over 40 themed pavilions, including a new Hard Pure Gold PavilionThe twin shows attract strong global industry support, with exhibitors participating from over 40 regional and industry pavilions. Participating regions include Chinese Mainland, Taiwan, India, Israel, Korea, Myanmar, Singapore, Sri Lanka, Thailand, Uzbekistan, Belgium, Germany, Italy, Spain, Türkiye, Brazil, Colombia, Mexico and the United States, etc.The World Gold Council debuts the Hard Pure Gold Pavilion, featuring a total of 11 exhibitors from Chinese Mainland, showcasing innovative gold craftsmanship to the global market. The pavilion aims to leverage the fairs as a springboard for international expansion.The Hong Kong Watch Manufacturers Association Ltd will participate as a pavilion for the first time, while the Zhushan Turquoise pavilion from Hubei will also make its debut. Other returning participants include the Tanzanite Foundation, the International Colored Gemstone Association (ICA), the Asia Pacific Creator Association, and the Asia Jewellery Culture Design and Crafts Association. The Hong Kong Jewellery & Jade Manufacturers Association will once again join forces with the Italian Exhibition Group (IEG) to present advanced jewellery manufacturing equipment and technologies.International brands in the spotlightThe Hall of Fame at the Hong Kong International Jewellery Show makes a highly anticipated return this year with more than 40% expansion in scale. It will welcome renowned international jewellery brands and help enhance global brand exposure. Turkish diamond jewellery brand Zen Diamond (Booth: CEC 3B-C12) presents diamond ring collections featuring exquisite cutting techniques. At the Hall of Extraordinary, Hong Kong exhibitor Continental Diamond Company (Booth: CEC GH-C07) showcases an 18K white and rose gold ring set with blue and light pink diamonds. Another Hong Kong exhibitor, Unique Brilliant Ltd (Booth: CEC GH-C13), unveils a necklace and earring set, the rubies display the coveted “pigeon blood red” colour.Oriental Aesthetics showcases cultural heritage craftsmanshipThis year’s shows will feature numerous jewellery pieces inspired by Asian culture and heritage. Chinese Mainland exhibitor, Guangdong JIABAO Pavilion Jewellery (Hong Kong) Company Ltd (Booth: CEC GH-A16) presents an 18K gold, handmade filigree butterfly brooch, made with national intangible heritage craft, with each piece taking over four months to complete. Another Chinese Mainland exhibitor, Shenzhen Meifei Precious Metals Co Ltd (Booth: CEC 3E-E02), brings a “Palatial Modern Chinese Style” jewellery series incorporating six traditional gold techniques, blending heritage craftsmanship with modern jewellery design.In recent years, hard pure gold technology has gained strong momentum in Chinese Mainland. Its high purity and enhanced hardness enable lighter, more durable designs with modern aesthetics. A seminar organised by the World Gold Council will examine the latest developments in the global gold market and hard pure gold technology.During the fairs, a series of events spotlighting Oriental aesthetics in jewellery will be staged. Hong Kong International Fashion Chuk Kam Jewellery Design Competition 2026, organised by the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited, encourages designers to create commercially viable and culturally rich gold jewellery for young consumer markets in ASEAN and the Middle East. Its award presentation ceremony will be held during the fairs.In addition, the inaugural International Fei Cui Jewellery Design Competition 2026, organised by the Hong Kong Jade Association, will also host its awards presentation during the fairs.Creative design sets the trendInnovative and trend-driven products help the industry stand out. Austy Lee Company Ltd (Booth: CEC 1E-F32) introduces bangles inspired by zebra patterns for the Year of the Horse. Designer Galleria welcomes new exhibitor Zheng Hong Collective (Booth: CEC 1CON-067A), featuring a brooch whose movable wings and tail sway with the wearer.The 27th Hong Kong Jewellery Design Competition, themed “Pure Elegance – Natural Beauty”, returns to nurture creative talent. Local students and industry professionals interpret the beauty of nature and their design stories through their creations, highlighting the diverse facets of jewellery design. Winning designs will be announced during the fairs.Rare treasures dazzle across both showsAs always, the twin shows offer buyers an outstanding selection of antique and rare jewellery. At the Hong Kong International Jewellery Show, Hong Kong exhibitor Baroque Antique & Jewellery Limited (Booth: CEC CH-F13) presents a 1970s Buccellati pink sapphire suite, while World Coins Co., Ltd. (Booth: CEC CH-N12) showcases a 19th-century Italian bi-colour enamel diamond piece preserved in its original box for over 100 years. At the Hong Kong International Diamond, Gem & Pearl Show, German exhibitor Caram e.K. (Booth: AWE 8-F05) features an 18.98-carat AGL-certified natural pink sapphire, while Canadian exhibitor Korite Ammolite Ltd. (Booth: AWE 8-F35) displays an 18K gold AA-grade ammolite and diamond necklace.The Hong Kong International Jewellery Show will also host a seminar titled “The Origins of Style: Tracing the Imprint of Time and Craftsmanship.” This seminar will invite British historian and jewellery authority Dr. Jack Ogden to speak. He will provide an in-depth analysis of the evolution of jewellery craftsmanship and changes in aesthetic tastes across different eras.Over 20 forums on hot topics including AI and digital marketingMore than 20 seminars and networking sessions will be held, covering industry trends, digital marketing and jewellery technologies. A session will examine how artificial intelligence moves from design to commercialisation to drive the development of the jewellery industry. There will also be seminars where influencers share how to leverage e-commerce platforms to enhance jewellery brand visibility, boost sales, and share practical experience, to help the industry accelerate the integration and synergy between online and offline channels.Business opportunities and industry exchangeThe exhibition attracts major international jewellery retail chains, as well as high-end, affordable luxury, and designer jewellery brands from around the world for sourcing. It creates business opportunities for both buyers and sellers while fostering industry exchange.The HKTDC has partnered with the Hong Kong Tourism Board and local enterprises to provide exclusive buyer privileges. These offers include dining, air tickets, and hotels, enabling buyers to enjoy Hong Kong’s unique charm while attending the fairs. The HKTDC will arrange free shuttle bus services between AsiaWorld-Expo and urban areas (including the Hong Kong Convention and Exhibition Centre in Wan Chai). For details, please refer to the fair’s official website.Combining online and offline services to facilitate sourcingThe shows use the EXHIBITION+ hybrid format. In addition to on-site procurement, the HKTDC’s AI-powered “Click2Match” will provide online business-matching for exhibitors and buyers from 23 February to 13 March. On-site buyers can use "Scan2Match" to scan exhibitors’ QR codes and continue discussions with exhibitors online during or after the show. To ease the buyer admission process, the HKTDC Marketplace App and the official websites of the two shows provide online verification functions. Buyers need only register through these platforms and upload a photo and valid identification to obtain a verified eBadge for direct entry, greatly reducing queuing times for onsite registration and verification and enhancing sourcing efficiency.Photo download: https://bit.ly/4ayrcAoAttending the press conference to introduce the twin jewellery shows today (5 February): Jenny Koo, HKTDC Deputy Executive Director (centre), Winston Chow, Chairman, HKTDC Jewellery Advisory Committee (left) and Kent Wong, Chairman, HKTDC Hong Kong International Jewellery Show and HKTDC Hong Kong International Diamond, Gem and Pearl Show Fair Organising Committee (right)Jenny Koo (front row, third left) took a group photo with members of the organising committee of the HKTDC Hong Kong International Jewellery Show and the Hong Kong International Diamond, Gem and Pearl Show, joined by celebrity guestArtist Hera Chan (third right) led a group of models to exhibit exquisite jewellery pieces from the showsArtist Hera Chan wore a natural Myanmar jadeite set presented by exhibitor On Tung Company. The exquisite ensemble featured a translucent emerald green jadeite and diamond necklace, ring, and earrings, showcasing a regal and graceful designThe phoenix features in traditional Chinese wedding jewellery, symbolizes auspiciousness and good fortune. Exhibitor Lao Feng Xiang Jewellery Hong Kong Limited presented a "China chic" wedding collection imbued with Oriental charm, crafting accessories that embody the imperial elegance of a royal court for womenWebsites Hong Kong International Jewellery ShowExhibition websitehttp://hkjewelleryshow.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkjewellery/tc/travel-to-fairground-hkcecActivity listhttps://www.hktdc.com/event/hkjewellery/tc/intelligence-hub  Hong Kong International Diamond, Gem & Pearl ShowExhibition websitehttp://hkdgp.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-aweActivity listhttps://www.hktdc.com/event/hkdgp/tc/intelligence-hubHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

Banle Group Hosts Inaugural ESG Forum with Industry Leaders, Pioneering Green Shipping Solutions Amid Global Decarbonization Push

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Banle Group (“Banle” or the “Group”), a leading Asia-Pacific marine fuel logistics provider, hosted its landmark inaugural ESG Forum — "Charting the New Horizon: Powering Green Shipping with Sustainable Fuels" — uniting top maritime executives, financiers, legal experts, and climate scientists to address the shipping industry's urgent decarbonization challenges on February 2.Speaker Lineup Tackles Critical IssuesThe forum featured exclusive insights from:Dr. Teck Lim Chia, Chairman and CEO of Banle GroupMs. Karen Cheah Yee-Lynn, Independent Director of Banle Group, Partner of Chooi & Company, Immediate Past President of the Malaysian Bar and EXCO Member of LAWASIAMr.Matt Liu Ming-Hsuan, SVP Capital Solutions, Cathay United BankDr.Wilson Cheung Wai-yin, Polar Explorer, Glaciologist and Policy Advisor, Polar Research and Expedition ConsultancyMs.Rebecca Zhang, Senior Manager Sustainable Finance, Commercial Banking, Hong Kong, HSBCThe forum served as a dynamic platform for thought leadership and dialogue, featuring a series of presentations addressing critical topics such as the impact of climate change on global shipping, evolving sustainability-related regulations, and innovative green and sustainability-linked financing solutions.Dr.Teck Lim Chia addressed in the keynote speech, “The global shipping industry stands at a pivotal moment. Rapid regulatory changes, geopolitical tensions, climate challenges, and technological advancements are reshaping the landscape at unprecedented speed. Yet, we are dedicated to fostering a collaborative environment where stakeholders can come together to share insights and develop strategies for a more sustainable future.”On the forum, Ms.Karen Cheah talked about how ESG has become a legal, economic, and moral imperative to safeguard planetary health – and how governments, businesses, courts, and capital markets at an international level must work together holistically to turn sustainability from aspiration into measurable action. She said, “We must establish planetary health metrics to track environmental, health, and risk impacts on all of us. This requires not only a measurement to gauge our progress but also a strategic plan to communicate these metrics, drive global awareness, and educate society at large. Moreover, we must integrate these metrics into governance structures at organizational, domestic, national, and international levels. We must engage in responsible business practices aligned with ESG components and ensure a robust framework for planetary health is implemented globally. Once we align collectively, we can systemize this framework for lasting impact.”Mr.Matt Liu shared his insight on integrating ESG features into financing strategies, “Green loans excel when companies have a clear, specific investment plan. Sustainability-Linked Loans (SLLs) operate under a distinct logic: their Key Performance Indicators (KPIs) must reflect material sustainability issues, be measurable, traceable, and independently verifiable. Crucially, Sustainability Performance Targets (SPTs) must balance ambition with feasibility, remaining achievable within the company’s operational capacity. Unlike green loans, SLLs do not restrict proceeds to green activities; instead, they demonstrate sustainability commitment through performance-linked financial mechanisms. Beyond loans and bonds, nearly all liability-style financial products can now integrate green or sustainability elements. This flexibility allows companies to align financing with sustainability goals while maintaining operational practicality, driving both environmental progress and financial innovation.”Dr.Wilson Cheung addressed his dedication to geoscientific education and advocacy, and talked about the responsible opportunities for the shipping industry, “Responsible opportunities in the shipping industry begin with recognising that the Arctic is not only a shortcut, but also a living homeland and a fragile climate regulator for the planet. New polar sea routes can reduce transit time and fuel use, yet they cross waters where infrastructure is scarce, ecosystems are vulnerable, and Indigenous communities depend on sea ice for culture and survival. True leadership means investing in cleaner fuels, ice-class vessels, and robust search-and-rescue capacity, while strictly limiting black carbon emissions and respecting international polar regulations. It also means listening to local knowledge that has guided safe travel on ice for thousands of years and integrating that wisdom with modern science and satellite data. If the industry embeds ESG principles into every Arctic voyage, these emerging routes can become a model of responsible innovation rather than a new frontier of unchecked risk.”Ms.Rebecca Zhang shared recent shipping industry transition trends from a sustainable finance perspective: “Regulations are constantly evolving, and so must global efforts to tackle climate change and make maritime transport more sustainable. Innovative solutions are emerging, and shipowners are exploring alternative energy options such as biofuels, bio-LNG, and bio-gas. The development of clean technologies is accelerating the industry’s systemic shift towards sustainability.”The forum concluded with a lively and interactive networking among participants, who exchanged ideas and reaffirmed their collective commitment to advancing sustainable practices throughout the shipping industry.Banle Group's sustainability leadership by example through its operational practices was prominently showcased, highlighting its ongoing efforts to spearhead industry decarbonization and responsible practices. Through initiatives like its participation in the EcoVadis rating system and advocacy for diverse sustainable marine fuels, Banle continues to drive meaningful transformation across the shipping sector.Looking ahead, the Banle Group remains committed to hosting future forums that foster dialogue, innovation, and collaboration for a more sustainable maritime ecosystem.Dr.Teck Lim Chia added: "This is just the beginning. Banle will continue driving practical decarbonization solutions for our industry and clients."For more information about Banle Group and its sustainability initiatives, please visit www.banle-intl.com.Photo Caption 1: Dr. Teck Lim Chia (centre) presented souvenirs to all speakers and panelists as a token of appreciation.Photo Caption 2: Panelists engaged in a discussion on the theme: “Charting the New Horizon: Powering Green Shipping with Sustainable Fuels”. Ms. Karen Cheah (left) served as moderator, guiding the discussion while also contributing her insights as a panelist.Photo caption 3: Attendees gathered at the ESG Forum, showcasing a shared commitment to sustainable practices and innovative solutions in the shipping industry.About Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications, as well as EcoVadis Silver Medal.For more information, please visit: https://www.banle-intl.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

万利集团与行业领袖举办首届ESG论坛 在全球减碳浪潮下开创绿色航运解决方案

香港, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 亚太地区燃油供应服务商万利集团（以下简称（「万利」或（「集团」）于2月2日举办以「开拓新视野：以可持续燃料推动绿色航运」为主题的首届环境、社会与治理（ESG）论坛。论坛汇聚航运高管、金融家、法律专家及冰川学家，共同探讨应对航运业迫切减碳挑战的方案。以下演讲嘉宾阵容于论坛探讨关键议题，分享独特见解：万利集团主席兼行政总裁谢威廉博士万利集团独立董事、Chooi & Company合伙人、马来西亚大律师公会前会长及LAWASIA执行委员会委员谢依玲女士国泰世华银行资本市场暨顾问部协理刘名轩先生极地探险家、冰川学家及政策顾问、Polar Research and Expedition Consultancy创办人／冰川学家与远征总监张伟贤博士汇丰香港工商金融可持续金融高级经理张雯瑾女士是次论坛为思想领袖提供了一个互动及对话的平台，并透过演讲嘉宾的专题讲座探讨若干关键议题，包括气候变化对全球航运的影响、持续转变的可持续发展相关法规，及创新绿色及可持续发展挂钩融资解决方案。谢威廉博士在主题演讲中表示：「全球航运业正处于关键时刻，迅速转变的监管法规、紧张的地缘政治局势、气候挑战及技术发展正以前所未有的速度重塑行业格局。因此，我们期望打造一个协作环境，让持份者聚首一堂，分享见解并制定策略，以构建可持续未来。」在论坛上，谢依玲女士讨论ESG如何成为保障地球健康的法律、经济和道德必要条件，并强调政府、企业、法院及资本市场必须在全球层面上通力合作，将可持续发展愿景转化为可量化的实际行动。谢女士表示：「我们必须建立全球健康指标体系，以系统追踪环境影响、健康影响及风险对全人类的综合作用。这不仅需要量化工具评估进展，更需制定战略传播方案以提升全球认知、推动全民教育。同时，必须将指标体系深度融入组织、国家及国际治理架构，在本土和全球层面同步实施。企业应践行负责任的商业伦理，全面对标ESG准则，构建普适性的全球健康框架。唯有通过全球协同标准化，方能实现框架的系统化落地与长效运行。」刘名轩先生分享其对将ESG特征融入融资策略的见解：「绿色贷款（Green Loans）在企业拥有明确、具体的投资计划时尤其适合。可持续发展挂钩贷款（Sustainability-Linked Loans，SLLs）遵循独特的逻辑：其关键绩效指标（KPIs）必须反映重大的可持续议题，并且可量化、追踪和独立验证。最重要的是，可持续性绩效目标（Sustainability Performance Targets，SPTs）必须在『积极进取』和『实际可行』之间取得平衡，确保在公司的运营能力范围内有机会实现目标。与绿色贷款不同，SLLs不限制所得款项只用于绿色活动上；相反，SLLs通过与绩效挂钩的金融机制展示可持续承诺。除了贷款和债券，几乎所有负债型金融产品现在都可以加入绿色或可持续性元素。这种灵活性使得企业能够将融资与可持续目标结合在一起，一方面保持运营的实际可行性，也能推动环境进步与金融创新。」张伟贤博士分享其对地球科学教育与倡导的坚定承诺，并探讨航运业的负责任发展机遇：「航运行业的可持续发展机遇始于认识到北极不仅是一条捷径，更是一个生机勃勃的家园和地球脆弱的气候调节器。新开通的极地航线虽能缩短运输时间、降低燃油消耗，但其航经水域存在基础设施匮乏、生态系统脆弱、原住民依赖海冰维系文化与生存等挑战。真正的领导力意味着要投资于更清洁的燃料、冰级船舶和强化搜救能力，同时严格限制黑碳排放（Black Carbon Reduction），并尊重国际极地法规。这也意味着倾听在冰上安全旅行了数千年的地方知识，并将这种智慧与现代科学和卫星数据融合。如果行业将ESG原则嵌入到每一次北极航行中，这些新兴航线能够成为可持续创新的典范，而非不受控制风险的新边界。」张雯瑾女士从可持续金融角度分享航运业转型趋势：「监管不断变化，应对气候目标和实现可持续海洋运输的策略亦需要与时并进。目前，创新方案也应运而生，船东群体正探索生物燃料、生物液化天然气（bio-LNG）、生物沼气等替代能源方案。清洁技术研发持续，有助推动全球航运业向可持续模式的系统性转型。」论坛在与会人士热烈交流中圆满结束，除交流意见外，他们亦重申对推动航运业可持续发展的共同承诺。万利集团在可持续发展领域的领导地位突出，显示其在引领行业减碳与推行负责任实践方面的不懈努力。集团亦透过参与EcoVadis永续性评级系统及支持多元化可持续船用燃料，持续推进航运业的有效转型。展望未来，集团将继续举办更多论坛，促进对话交流、创新及合作，从而建立更可持续的海洋生态系统。谢威廉博士补充：「以上不过是个开端，万利将继续为行业及客户制定切实可行的减碳解决方案。」有关万利集团及其可持续发展方案的更多讯息，请浏览 www.banle-intl.com。图片说明1：谢威廉博士（中）向演讲嘉宾及论坛成员致送纪念品以示感谢。图片说明2：论坛成员就「开拓新视野：以可持续燃料推动绿色航运」主题进行讨论。谢依玲女士（左）担任主持人，引领讨论并以论坛成员身份分享见解。图片说明3 ：与会人士在 ESG 论坛上聚集，展现了对航运业可持续实践和创新解决方案的共同承诺。关于万利集团万利集团成立于 2015 年，以CBL International Limited（纳斯达克：BANL）在纳斯达克股票市场上市。我们致力于为客户提供一站式燃油供应服务，被业内称为燃油供应服务商。我们主要通过当地实体供货商为船舶提供燃油加注服务，遍布比利时、中国、香港、印度、日本、韩国、马来西亚、毛里裘斯、巴拿马、菲律宾、新加坡、台湾、泰国、土耳其和越南，共覆盖65个港口。集团积极推动可持续燃料，并已取得ISCC EU和ISCC Plus认证，以及EcoVadis银奖。如欲了解更多信息，请到集团网站 https://www.banle-intl.com 浏览。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

卓正医疗上市在即：认购火爆 以独特商业模式撬动业绩逆势增长

香港, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 随著居民健康消费意识持续提高和消费升级，中国私立医疗服务市场，特别是私立中高端医疗服务机构迎来发展窗口。 其中，卓正医疗控股有限公司（"卓正医疗"，股份代号：2677.HK）以独特的家庭医疗模式为核心，融合全科室服务覆盖与线上线下一体化体验，深耕中高端市场多年，已成长为行业领先企业之一。2月3日，卓正医疗结束港股招股，发售价定为66.60港元，预计于2月6日正式登陆港交所。招股期间，公司市场认购热情持续高涨，据富途公开数据显示，其孖展认购额高达665.29亿港元，约超购2103.31倍，成为近期港股市场中备受追捧、认购火爆的新股，机构与个人投资者踊跃布局，用实际行动彰显对公司商业模式、行业地位及未来增长前景的坚定信心。从"个人诊疗"到"家庭入口"：平台化生态铸就增长基石在中高端健康服务赛道竞争日趋激烈的当下，卓正医疗跳出传统医疗机构的发展模式，以家庭为核心深耕高价值会员体系，打造独树一帜的"超级用户"生态，实现复购率与忠诚度双双领跑行业，构筑起坚实的品牌与市场壁垒。不同于传统医疗机构单人单次的低频消费模式，卓正医疗通过整合儿科、齿科、眼科、皮肤科、内科及妇科等超过六大核心专科，为同一家庭的不同成员提供一站式、跨生命周期的健康解决方案，让自身从一个解决特定健康问题的"站点"，转变为一个家庭健康管理的"总入口"和决策中心。当单一家庭成员获得信任并建立服务关系后，带动其他家庭成员自然导入，实现了客户基础的有机扩张和消费场景的极大延伸。这种平台化生态显著提升了客户生命周期价值，推动公司收入持续增长。在"家庭入口"的平台上，卓正医疗进一步通过"卓正会员计划"深化用户关系，将平台流量高效转化为长期、高粘性的"超级用户"。该计划为家庭提供优先预约、专属套餐等权益，不仅提升了服务体验，更在心理层面建立了"健康管家"式的信任纽带，持续提升用户粘性。截至2025年8月31日，公司已拥有超过11.6万个会员帐户，会员续费率达67%，而整体患者回头率高达82.7%，印证了其服务模式强大的客户锁定能力。财务表现逆势增长 数字化 AI 化重塑服务新范式凭借独特的商业模式与高效的运营管理，卓正医疗在医疗服务行业部分机构面临盈利压力的背景下，实现了收入与利润的双重逆势增长。数据显示，2022年至2024 年，卓正医疗营收从4.7亿元增长至9.6亿元，复合年增长率达42.3%，营收规模实现翻倍增长；毛利从4398万元跃升至2.3亿元，复合年增长率高达126.7%，盈利能力大幅提升；2024年，公司更是成功扭亏为盈，经调整净利润1,070万元，实现了从规模增长到盈利增长的质的飞跃。尤为难得的是，卓正医疗的业绩增长并非依赖医保加持或高额营销投入，其营销费用占收比常年维持在2%上下，真正依靠口碑获客实现可持续增长，这种健康的盈利模式也成为资本市场看好公司的重要原因。而数字化与AI技术的深度应用，则为卓正医疗提升运营效率、打造高粘性健康服务生态提供进一步助力。公司自主搭建了HMS医院管理系统、DMS卓正管理系统、卓正数据中台等数字化平台，实现集中化、标准化及数字化的管理，不仅大幅提升医护人员的运营效率，更让用户享受到便捷、高效的诊疗体验，进一步提升了用户满意度。此次港股IPO，卓正医疗计划将把募资净额的35%用于医疗人工智能应用的人才培养、技术研发与外部合作，旨在通过AI技术赋能，革新医疗服务提供方式与运营效率。未来，随著AI技术与医疗服务的深度融合，卓正医疗有望进一步优化使用者体验，提升服务效率，让数字化、智能化成为公司持续增长的新引擎。从千亿健康消费赛道的稀缺标的，到认购火爆的港股IPO新星，卓正医疗的资本市场之路，是其多年深耕高价值健康服务、坚持质量与口碑的必然结果。凭借高复购高忠诚的超级用户生态，公司构筑了行业领先的商业模式壁垒；逆势增长的财务表现，印证了其盈利模式的可持续性；借助数字化与AI化的前瞻布局，公司有望打造了高粘性的健康服务新范式，为长期增长注入强劲动力。在资本赋能下，公司有望进一步夯实自身在中高端健康服务赛道的龙头地位，其上市后的表现，值得长期关注。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

Annature Launches 21 CFR Part 11 Compliant Digital Signatures to Support FDA-Regulated Organisations

BRISBANE, AUS, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - Annature, Australia's leading eSignature and Identity verification provider, has announced the release of its 21 CFR Part 11 compliant electronic signature module, enabling organisations operating in FDA‑regulated environments to execute electronic records with confidence.The new capability ensures Annature customers can meet the U.S. Food and Drug Administration's requirements for electronic records and electronic signatures under 21 CFR Part 11, a regulation that governs data integrity, signer authentication, and auditability across industries such as life sciences, pharmaceuticals, biotechnology, and clinical research.The release has been driven by growing demand from U.S.-based and multinational organisations seeking a modern, compliant alternative to legacy eSignature platforms. Several customers operating in regulated environments have already transitioned to Annature as part of broader digital transformation initiatives, prompting the company to formally introduce Part 11 support as part of its international product roadmap."As we continue to grow globally, it's critical that Annature supports the regulatory frameworks our customers operate under," said Corey Cacic, CEO of Annature. "Our 21 CFR Part 11 module allows organisations subject to FDA requirements to use Annature with confidence, knowing their electronic signatures meet the necessary compliance standards."The module introduces controls aligned with Part 11 expectations, including secure signer authentication, tamper‑evident audit trails, and strong linkage between electronic signatures and the records they relate to. These features ensure electronic signatures executed through Annature can be relied upon in regulated workflows and during regulatory review.Kim Steel, Founder and Managing Director of SAPRO - a boutique CRO supporting niche biotech and pharmaceutical companies with commercially sponsored Phase I-III full-service clinical trials has welcomed the release."For organisations operating in regulated environments, compliance with 21 CFR Part 11 is not optional - it is fundamental," said Steel. "It is encouraging to see Annature, an Australian technology provider supporting international regulatory requirements that are critical to our industry and our clients. Solutions like this enable sponsors to operate confidently on a global stage, without reliance on outdated or overly complex legacy systems, while remaining inspection and audit-ready at all times."The launch further strengthens Annature's position as a global‑ready eSignature platform, supporting organisations that operate across jurisdictions with varying compliance obligations. The 21 CFR Part 11 module is available now and can be enabled for customers who require FDA‑compliant electronic signatures.About AnnatureAnnature is Australia's leading eSignature and Identity verification provider, trusted by over 6,700 businesses. With a Pay as you go model and deep integration across the business app ecosystem, Annature delivers secure, affordable, and locally supported solutions for professionals across the country. Annature's growing product suite also includes integrated payments and compliance features designed to support both domestic and international regulatory requirements.https://www.annature.com.auCONTACT:Name: Corey CacicEmail: corey@annature.com.auSOURCE: Annature Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

AGFA HealthCare Named Best in KLAS(R) 2026 Across Three Enterprise Imaging Segments in the United States

MORTSEL, BE, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide.The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights.AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinical decision-making through connected, high-performing access to images and data.Best in KLAS® - Enterprise Imaging (United States)Enterprise Imaging for Radiology: ranked #1 with a 93.2% score in the PACS (Small - under 300k studies) segment.XERO® Viewer: ranked #1 with a 92.1% score in the Universal Viewer (Imaging) segment for the third consecutive yearEnterprise Imaging VNA: ranked #1 with a 89.8% score in the Vendor Neutral Archive (VNA) segment for the second consecutive year."Being recognized across three Enterprise Imaging segments - including multiple consecutive wins - is a powerful affirmation of our clinician-first strategy," said Nathalie McCaughley, President of AGFA HealthCare. "Healthcare organizations trust us to deliver imaging environments that truly support clinicians in their daily work, while enabling IT and clinical leaders to operate with confidence, performance, and long-term vision. This recognition reflects the strength of our partnerships and our unwavering focus on empowering care teams through connected, intelligent imaging."Commenting on the awards, Adam Gale, CEO of KLAS Research, said:"The Best in KLAS winners have earned the trust of their customers over the past year. With this recognition, they set the standard for excellence through partnership in healthcare technology and services in the months to come."Monique Rasband, Global Vice President of Imaging at KLAS Research, added:"AGFA HealthCare's strong performance across multiple Enterprise Imaging segments reflects consistent customer feedback. Organizations recognize the value of solutions that help imaging teams work efficiently today while providing a clear path for future growth and innovation."The Best in KLAS awards are based on direct feedback from healthcare providers and recognize vendors who consistently demonstrate excellence through partnership, performance, and responsiveness to customer needs.AGFA HealthCare will celebrate its Best in KLAS recognition during HIMSS 2026, alongside customers and partners, as part of its continued commitment to advancing connected, intelligent, and human-centered imaging at scale.KLAS referencesBest in KLAS Awards overview: 2026 Best in KLAS Awards: Software and Services ReportEnterprise Imaging segments reports: 2026 Best in KLAS Awards: Software and Services ReportAbout AGFA HealthCareAt AGFA HealthCare, we understand that striking the critical balance between clinical efficiency and quality patient care starts with the clinician experience. We recognize how vital it is for clinicians to be fully immersed in their cases, channeling all their energy into delivering confident, informed diagnoses. That's why we designed our Enterprise Imaging platform to eliminate the barriers that get in the way. When distractions melt away, technology feels like an extension of one's thought process, and each clinician has everything they need to perform at the top of their craft. That's life in flow.This belief shapes everything we do - guided by our Mission, Vision, and Customer Delivery Principles, which are designed to empower clinicians and elevate their experience.AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.comand follow us on LinkedIn.AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO is a registered trademark of Agfa HealthCare N.V. Belgium or its affiliates. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.About KLAS ResearchKLAS Research is a leading healthcare IT data and insights company dedicated to improving global healthcare delivery by amplifying the voice of healthcare providers. Celebrating its 30th anniversary in 2026, KLAS evaluates vendor performance through independent research based on direct customer feedback.Best in KLAS® is a registered trademark of KLAS Research.Press Contact: Jessica Baldry, Global Marketing & Communications Manager, AGFA HealthCare +44 1206 413052 jessica.baldry@agfa.comSOURCE: Agfa HealthCare Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

Goldenstone Acquisition Limited (Ticker: GDST) Announces Intent to Merge with ESG Packaging Innovator Deluxe Technology Group, Targeting 2026 NASDAQ Listing

HONG KONG, Feb 4, 2026 - (ACN Newswire via SeaPRwire.com) – NEW YORK, TAIPEI and TOKYO, Goldenstone Acquisition Limited (Ticker: GDST) (“Goldenstone”), a special purpose acquisition company listed in the U.S. capital market, today announced the execution of a letter of intent (LOI) for a proposed business combination with Deluxe Technology Group (“Deluxe”), a Taiwan-based leader in green technology machinery and sustainable material solutions. The merger is poised to capitalize on the rapidly growing sustainable packaging market, which is projected to reach over $250 billion by 2035.Amidst a complex global regulatory landscape and increasing consumer demand for eco-friendly products, Deluxe has distinguished itself by developing a proprietary and vertically integrated business model. The company’s patented pulp molding formula as well as technology, and use of agricultural waste as a raw material directly address the industry’s most pressing challenges: cost, performance, and scalability. This strategic approach has allowed Deluxe to achieve a significant breakthrough without geographical boundaries by offering compostable product lines that are not only environmentally superior but also cost-competitive with traditional plastics.“Deluxe Technology Group is not just participating in the green transition; they are leading it,” said the CEO of Goldenstone Acquisition Limited. “In a market where many companies struggle with the high cost and inconsistent supply of sustainable materials, Deluxe has created a scalable and economically viable solution. Their ability to turn agricultural waste into high-performance, cost-effective packaging is a game-changer for the industry. We are confident that this merger will unlock significant value for our investors and accelerate the global adoption of sustainable packaging.”The proposed merger is further strengthened by a strategic partnership with Oji Holdings Corporation (“Oji”), a Japanese pulp and paper manufacturing leader. This collaboration secures a stable supply of high-quality raw materials for Deluxe, mitigating a key risk that has hindered the growth of many other sustainable packaging companies. The partnership aligns with Oji’s commitment to contribute the “Harmony with Nature and Society” and will leverage Deluxe’s advanced technology to expand its global footprint.Deluxe’s forward-thinking strategy is also reflected in its recent expansion into the United States, establishing a physical presence to better serve its North American customer base, which includes several Fortune 500 companies. This move is particularly timely, as the North American compostable packaging market represented the largest share in 2025, at around 30% of the global market.“Our mission has always been to prove that sustainability and profitability can go hand in hand,” said Jason Lai, Founder and CEO of Deluxe Technology Group. “With over 130 patents and 20 global awards, our technology is a testament to this vision. By partnering with Goldenstone, we are gaining a strategic partner that will help us to navigate the public markets and to scale our solutions to meet the growing demand from the world’s largest brands. Together, we will accelerate the transition away from single-use plastics and create a more sustainable future.”Under the terms of the LOI, Goldenstone and Deluxe will work exclusively towards the negotiation and execution of a definitive merger agreement. The transaction is subject to due diligence, the execution of definitive agreements, and customary closing conditions, including regulatory and shareholder approvals. The proposed merger aims for a completion and subsequent public listing on the NASDAQ in 2026.Advisors and UnderwritersLoeb & Loeb LLP is serving as legal counsel to Goldenstone Acquisition Limited. MarcumAsia is serving as the Company’s auditor. Maxim Group LLC is acting as the financial advisor for the transaction. Chi Advisory Limited is serving as a financial advisor to Deluxe.About Goldenstone Acquisition Limited (Ticker: GDST)Goldenstone Acquisition Limited is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. Goldenstone Acquisition Limited completed its US$57.5 million initial public offering on March 17, 2022, with about US$5.3M trust account balance as of September 30, 2025.About Oji Holdings Corporation (TYO: 3861)Oji is a leading Japanese company committed to resource sustainability and industrial innovation. Grounded in their philosophy to contribute to the "Creation of Innovative Value" and "Harmony with Nature and Society," Oji serves as both a strategic investor and a primary supplier of premium pure pulp to Deluxe, facilitating global expansion and environmental stewardship.About Deluxe Technology GroupHeadquartered in Taiwan with operations expanding into the US, Deluxe Technology Group is a premier provider of green technology machinery and sustainable product solutions. Specializing in pulp molding formula and ESG Technology, the company offers a complete turnkey solution. With over 20 global awards, and more than 130 patents, Deluxe provides compostable alternatives to plastic that are produced with industry-leading energy efficiency, with select products offering superior cost-competitiveness to plastic. Deluxe is supported by a prestigious consortium of institutional investors, validating Deluxe’s potential to lead the global green transition. Key investors include GIC (Government of Singapore Investment Corporation), Sigma Global Fund, JAFCO Asia, Oji Holdings Corporation, SBI & Capital 22, Cathay Private Equity, and Delta Electronics.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This includes statements regarding the intent to enter into a definitive agreement and the timeline for a 2026 merger. These statements are based on various assumptions and the current expectations of the management of Goldenstone and Deluxe and are not predictions of actual performance. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Goldenstone and Deluxe.No Offer or SolicitationThis press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction where such offer, solicitation, or sale would be unlawful under the securities laws of any such jurisdiction.Contact Information:Investor Relations: Goldenstone Acquisition Limited Email: eddie@windfallusa.comEmail: ir@chi-am.comMedia Contact: Deluxe Technology GroupEmail: media@deluxe-tech.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

SuperX Strengthens Japan Presence to Explore AI Data Center Projects with Local Partners

OSAKA, Japan, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – February 4, 2026, SuperX Industries Co., Ltd. ("SuperX"), a Japanese subsidiary of SuperX AI Technology Limited (“NASDAQ:SUPX”), today announced the signing of an Memorandum of Understanding ("MOU") on February 4, 2026 with Digital Dynamic Inc. ("DD"), eole Inc. ("eole"), and Woodman Inc. ("Woodman"). This MOU builds on the parties’ prior cooperation to establish a comprehensive framework for the co-development of large-scale AI Data Centers (AIDC) across Japan.Advancing the Mie Prefecture Pilot ProjectFollowing the first MOU signed on January 30, 2026 in Osaka, Japan, the Parties entered into the MOU to further deepen collaboration by establishing a joint task force to pilot an AIDC project in Mie Prefecture, Japan with an initial facility capacity up to 4MW, subject to feasibility assessments, site conditions, regulatory approvals, and the execution of definitive agreements. The pilot initiative is intended to serve as a starting point for assessing potential future expansion up to 300MW in total capacity.Addressing Japan’s AI Infrastructure BottleneckThe shift toward modular architecture directly addresses Japan’s growing demand for the expansion of domestic AI capacity on an accelerated timeline. Unlike traditional "brick-and-mortar" builds that can take years to complete, SuperX’s modular approach accelerates deployment by reducing construction timelines significantly. This new pilot project is designed to be purpose-built for next-generation, liquid-cooled GPUs—capabilities often lacking in legacy data centers.Scalable delivery and reliable operationsPursuant to the MOU, the Parties intend to collaborate on the system-level integration of critical infrastructure, including advanced power systems and liquid cooling solutions essential for continuous AI workloads. The framework also contemplates the future integration of renewable energy components, such as solar and wind power, energy storage systems, and grid interconnection, subject to site conditions, commercial viability and regulatory approvals.To facilitate execution, a joint task force is expected to be established to define technical architecture, governance, and near-term milestones. SuperX will lead the provision of the modular system architecture and power system integration.Executive quote“Speed-to-market is the new currency in the AI race,” said Aiko Furukawa, the CEO of SuperX Industries Co. Limited. “This pilot project in Mie Prefecture is intended to demonstrate how we can deploy AI infrastructure with speed. Alongside our partners, we aim to demonstrate that modular scalability is the most viable path to meeting Japan's surging demand for AI.”Looking aheadLooking forward, the Parties intend to use the initial pilot as a reference framework to evaluate broader modular AIDC opportunities across Japan, including scalable pathways for expansion—subject to further feasibility assessments, regulatory approvals, site conditions, and the negotiation and execution of definitive agreements.About Digital Dynamic IncDigital Dynamic Inc. is one of Japan’s fastest-growing AI infrastructure operators, with a rapidly expanding deployment of NVIDIA-based inference GPU resources. In 2026, the company plans to complete AI data centers in Kagoshima Prefecture and Fukushima Prefecture, reinforcing Japan’s next-generation AI computing foundation.About eole Inceole Inc. is a publicly listed company in Japan with a rapidly growing presence in the domestic GPU server market. The company provides investment and business development support for AI data center development projects, playing an active role in advancing Japan’s AI infrastructure ecosystem.About Woodman IncWOODMAN Inc. is a Japanese technology company focusing on eliminating societal waste by transforming underutilized resources, such as surplus electricity and computing power, into new value. They specialize in constructing optimized computing environments for AI and HPC (High-Performance Computing), bridging the gap between energy infrastructure and, previously, blockchain/mining hardware.About SuperX AI Technology Limited (NASDAQ:SUPX)SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sgSafe Harbor Statement This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

云顶新耀宣布与麦科奥特达成MT1013独家商业化许可协议

上海, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK，以下简称"公司"），一家专注于创新药研发、临床开发、制造及商业化的生物制药公司，今日宣布与陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）签署独家商业化许可协议，获得MT1013在中国及亚太区（日本除外）的独家商业化授权。MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体(CaSR)及成骨生长肽(OGP)受体，开发主要用于治疗继发性甲状旁腺功能亢进症(SHPT)。此次战略合作将与云顶新耀现有肾科管线形成协同效应，强化产品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾病拓展至更广泛的慢性肾脏病领域。根据协议，云顶新耀将向麦科奥特支付人民币2亿元首付款，以及最高不超过人民币10.40亿元的潜在监管及商业里程碑付款。中国III期临床研究正在进行中，相关临床开发费用将由麦科奥特承担。MT1013是由麦科奥特自主研发的全球首创双靶点多肽新药，2025年获美国肾脏病学会（ASN）年会"Late-Breaking"收录。其开创性地融合了"钙敏感受体（CaSR）+成骨生长肽（OGP）模拟"双重作用机制，解决了PTH、钙、磷代谢平衡的问题，这一全新设计使其在治疗继发性甲状旁腺功能亢进（SHPT）及相关骨代谢疾病时，首次创造性的从源头上控制病情，且能通过直接激活成骨通路，主动促进骨形成与修复，实现从"间接抑制骨吸收"到"主动促进骨生成"的治疗创新升级。临床研究证实，MT1013在慢性肾病接受维持性血液透析伴继发性甲状旁腺功能亢进患者中，起效迅速、效力强且持久，安全性良好，在综合达标率（iPTH, 血钙，血磷均达标）、血钙钙化指标的控制及心血管获益前景上均展示出超越现有疗法的潜力。目前，MT1013正在中国开展针对该患者群体的III期临床研究，已入组超50%。SHPT是慢性肾脏病（CKD）患者最常见的严重并发症之一。该疾病导致钙磷代谢紊乱、甲状旁腺激素升高、骨病变、血管钙化等一系列病理变化，显著增加骨折、心血管事件和死亡风险，是影响CKD患者预后的关键因素。随着全球慢性肾脏病患者规模持续扩大，SHPT及其相关治疗需求亦不断增长。数据显示，全球CKD患者人数已由2019年的9.052亿人增至2024年的10.655亿人，预计2030年将超12亿人，2035年将超15亿人；同期全球SHPT患者人数亦持续增长，预计2030年将达约1.899亿人，2035年将达约2.217亿人，临床需求亟待满足。云顶新耀董事会主席吴以芳表示："我们非常高兴能与麦科奥特达成此次合作。在全球慢性肾脏病患者持续增加的背景下，继发性甲状旁腺功能亢进仍存在显著临床未满足需求。MT1013作为具备全球首创双重作用机制的临床后期创新资产，有望为SHPT患者提供全新的治疗选择。作为潜在同类最佳药物，MT1013将与公司现有的肾科产品组合形成高度协同，进一步夯实公司在肾科领域的布局。云顶新耀在持续深耕自身免疫相关肾脏疾病的基础上，正加速拓展至肾小球肾炎以及慢性肾脏病及其并发症等更广泛的治疗领域。此次合作是公司完善创新管线、拓展肾科治疗边界的重要战略举措，标志着肾科战略由聚焦单一疾病领域向系统化和平台化的发展阶段升级。未来，双方将协同推进MT1013的开发与商业化，为更广泛的肾病患者提供创新治疗选择。"麦科奥特创始人、董事长王冰博士表示："我们很高兴与云顶新耀达成此次战略合作。云顶新耀在肾病领域拥有深厚的市场积累和成熟的商业化体系，是推动MT1013惠及中国乃至全球患者的理想合作伙伴。MT1013是公司多肽技术平台的重要成果，代表着公司在慢病创新治疗领域深耕的重要里程碑达成，其独特的双靶点机制有望为SHPT治疗带来突破和更多获益。我们期待与云顶新耀紧密协作，加速该产品的临床开发和上市进程，共同满足广大未满足的临床需求，开启肾病领域治疗的全新篇章。"MT1013已完成关键II期临床研究，数据显示，MT1013在维持性血液透析伴SHPT患者中，展现出强效且持久的iPTH抑制能力，并在与依特卡肽头对头比较中实现了综合管理的优势——其iPTH、血钙、血磷三项同时达标率更高，降磷及降低心血管风险标志物FGF-23的优势更强，加之MT1013在长达52周的治疗中也为患者人群带来了显著的骨密度提升及骨代谢标志物改善，逐步验证了其独特的双重机制在SHPT患者中综合管理及改善骨骼健康方面的潜在临床获益。目前MT1013已进入以西那卡塞为阳性对照的确证性III期临床试验。该III期试验已在全国范围内启动超过100家研究中心，计划招募约424名患者，主要针对慢性肾脏病维持性血液透析伴 SHPT的患者群体。关于MT1013MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体（CaSR）及成骨生长肽（OGP）受体，开发主要用于治疗继发性甲状旁腺功能亢进症（SHPT），并计划拓展至包括慢性肾病性矿物质和骨代谢异常（CKD-MBD）伴骨质疏松及未接受透析的SHPT在内的额外适应症。MT1013已于2025年5月完成针对SHPT的II期临床研究（MT1013-II-C01），并已进入以西那卡塞为对照的III期临床研究。关于云顶新耀云顶新耀是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，致力于满足全球市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业拥有深厚的专长和丰富的经验。公司在浙江嘉善拥有具备商业化规模的全球生产基地，并严格按照国家药品监督管理局（NMPA）和欧洲药品管理局（EMA）的 GMP 要求及世界卫生组织（WHO）PQ 标准建设。公司聚焦自身免疫、眼科、急重症及CKM（心血管、肾脏及代谢）等疾病治疗领域，已打造集全渠道商业化体系与药品全生命周期商业化能力于一体的商业化平台，并以拥有全球权益的自研 mRNA 平台为基础，持续推进mRNA in vivo CAR-T 与 mRNA 肿瘤疫苗等现有管线，同时通过引进及生态孵化潜力平台，拓展研发能力，同时强化全球化布局，加快国际化发展进程。更多信息，请访问公司官网：www.everestmedicines.com。关于麦科奥特陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）于2007年1月在西安成立，现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业，致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业，聚焦于心脑血管、代谢类疾病相关领域的新药研发。公司是是双特异性多肽概念的提出者、实施者、验证者和开发者，是多肽类药物研发的优秀平台之一，具有筛选多靶点多肽药物的特殊机制，具备开发First-in-class和Best-in-class品种的平台型研发能力，现已储备多个新药品种，其中进入临床研发的有7个原研创新药管线，包括1个临床三期阶段，3个临床二期阶段，3个临床一期阶段。公司致力于创制新药、挽救生命，满足未被满足的临床需求，用科技创新为人类健康保驾护航。更多信息，请访问公司官网：www.micot.cn。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ACN Newswire

TANAKA PRECIOUS METAL TECHNOLOGIES在体外诊断试剂等的各种检测试剂盒的受托制造中 确立全面解决方案体制

东京, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 专注于工业用贵金属展开业务的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.（总公司：东京都中央区、执行总裁：田中 浩一朗）宣布在以体外诊断试剂为代表的各种检测试剂盒的受托制造业务中，确立了可一站式应对整个工序的全面解决方案体制。TANAKA此前主要开展从检测试剂盒的开发制造到提取液的批量制造的相关业务，此次完善了提取液分装及包装的生产线，实现了在公司内部从开发到最终成品制造完成闭环的一条龙体制。由此不仅降低了外包和运输的相关成本，还缩短了生产周期，使我们能够以更短的期间提供更高质量的产品。此外，我们计划于2026年3月前追加引进最新型的自动装配生产线和提取液分装装置，以进一步扩大产能及缩短备货周期。TANAKA的全面解决方案体制通过强化一条龙生产体制实现灵活应对通过此次确立的全面解决方案体制，我们实现了从检测试剂盒开发制造，到提取液的批量制造及分装、包装等各工序的一站式受托服务。由此不仅能够对客户从开发阶段到量产的过程持续提供支持，还能应对仅药液分装等单一工序的委托。通过生产流程的公司内部闭环，来实现进一步强化稳定供应与质量管理。在广泛的疾病领域中的检测试剂盒的开发实绩与拓展示例我们提供针对流感、新型冠状病毒等呼吸道传染病，以及登革热病毒、寨卡病毒等范围广泛的传染病的体外诊断试剂。这些检测试剂盒可应对唾液、血液、尿液等多种检体，为在医疗领域实现快速精准的诊断提供支持。呼吸道传染病蚊媒传染病妇产科・流感病毒・腺病毒・RS病毒・人偏肺病毒・新型冠状病毒・A群β溶血链球菌（溶连菌）・登革热病毒・寨卡病毒・基孔肯雅热病毒・怀孕检测试剂TANAKA可检测疾病领域拓展示例技术基础与今后的展望TANAKA自2006年左右开始研发体外诊断试剂，不断培养以金（Au）胶体粒子为核心的相关技术。已拥有蛋白质固定化技术、非特异性吸附抑制技术、抗原抗体反应增强技术等，通过免疫层析法实现试剂更高性能化的多种技术。此外，还依托ISO 13485认证，有效利用这些技术，承接更高质量检测试剂盒的委托制造。今后仍将充分利用这一全面解决方案体制，在与合作伙伴企业协作的同时，致力于新型诊断试剂的开发工作，并为解决社会课题和推动医疗领域的发展做出贡献。关于TANAKATANAKA自1885 年（明治18年）创业以来，营业范围以贵金属为中心，并以此展开广泛活动。公司在日本国内拥有非常可观的贵金属交易量, 长年以来不遗余力地进行工业用贵金属制品的制造和销售，以及提供作为宝石饰品及资产的贵金属商品。并且，作为贵金属相关的专家集团，日本国内外的各集团公司进行制造、销售以及技术一体化，携手合作提供产品及服务。2024年度（截至2024年12月)集团总营业额为8,469亿日元，拥有5,591名员工。产业事业全球网站https://www.tanaka.com.cn产品咨询表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://www.tanaka.com.cn/inquiries-on-industrial-products/新闻媒体咨询处TANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.com.cn/inquiries-for-media/新闻稿: https://www.acnnewswire.com/docs/files/20260205_CH.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE.NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com